Scholarlink

<p>We aimed to establish and evaluate a method for measuring the cardiac implantable electronic devices (CIEDs) dose of radiotherapy patients using radiophotoluminescence glass dosimeters (RPLDs). Thirty-two treatment courses of thirty patients were analyzed. The relationships between the CIEDs dose and the treatment site locations were analyzed, and the RPLD doses were compared to the treatment planning system (TPS) doses for head and neck or chest cases (<i>n</i> = 18). A phantom study was conducted in five cases wherein the dose discrepancies between RPLD and TPS in all fractions were more than double and 5&#xa0;cGy or more, and filter of energy dependence correction of RPLDs was evaluated. The longer the distance between the irradiation field and the CIEDs, the lower the doses, and it was approximated by a function of the power law of distance from the field edge. In eighteen cases where TPS and RPLD doses could be compared, the dose discrepancies per prescribed dose between RPLD measurements and TPS calculations were within 1.15%, with a 95% confidence limit of 0.6%. In the phantom study, the dose discrepancies between the RPLD and TPS were decreased using filters for all five cases. In conclusion, in vivo dosimetry using RPLD was very useful as a means of avoiding the following risks: when planning CT did not include the CIED for dose calculation-based assessment; unintended direct exposure of the CIED to the treatment beam; furthermore, TPS dose calculation accuracy outside of the irradiated field remains an issue.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vivo dosimetry of cardiac implantable electronic devices with a radiophotoluminescent glass dosimeter in patients undergoing radiotherapy

  • 期刊论文

  • 发表日期：

    2026年6月21日

查看全文
  • Shohei Mikasa,
  • Hiroyuki Okamoto,
  • Yuki Miura,
  • Yusuke Watanabe,
  • Toshimitsu Sofue,
  • Satoshi Nakamura,
  • Takahito Chiba,
  • Kotaro Ijima,
  • Tetsu Nakaichi,
  • Mihiro Takemori,
  • Hiroki Nakayama,
  • Hiroshi Igaki

摘要

We aimed to establish and evaluate a method for measuring the cardiac implantable electronic devices (CIEDs) dose of radiotherapy patients using radiophotoluminescence glass dosimeters (RPLDs). Thirty-two treatment courses of thirty patients were analyzed. The relationships between the CIEDs dose and the treatment site locations were analyzed, and the RPLD doses were compared to the treatment planning system (TPS) doses for head and neck or chest cases (n = 18). A phantom study was conducted in five cases wherein the dose discrepancies between RPLD and TPS in all fractions were more than double and 5 cGy or more, and filter of energy dependence correction of RPLDs was evaluated. The longer the distance between the irradiation field and the CIEDs, the lower the doses, and it was approximated by a function of the power law of distance from the field edge. In eighteen cases where TPS and RPLD doses could be compared, the dose discrepancies per prescribed dose between RPLD measurements and TPS calculations were within 1.15%, with a 95% confidence limit of 0.6%. In the phantom study, the dose discrepancies between the RPLD and TPS were decreased using filters for all five cases. In conclusion, in vivo dosimetry using RPLD was very useful as a means of avoiding the following risks: when planning CT did not include the CIED for dose calculation-based assessment; unintended direct exposure of the CIED to the treatment beam; furthermore, TPS dose calculation accuracy outside of the irradiated field remains an issue.